HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Ascent ENT Group Holdings / Equity Capital Markets

<ul>
<li>For ENT services, the number of patients and scale of ENT field are relatively stable, with growth ceiling.</li>
<li>Due to the limited doctor resources in Singapore and the intensified multi-party competition faced by Ascent, there may not be exciting future growth potential.</li>
<li>So, we are conservative about the Company’s outlook if it just operates the business within Singapore or without diversifying its business effectively.</li>
</ul>


For ENT services, the number of patients and scale of ENT field are relatively stable, with growth ceiling.
Due to the limited doctor resources in Singapore and the intensified multi-party competition faced by Ascent, there may not be exciting future growth potential.
So, we are conservative about the Company’s outlook if it just operates the business within Singapore or without diversifying its business effectively.


Pre IPO Ascent ENT Group Holdings - Conservative About the Outlook

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ascent ENT Group Holdings (AEG HK)

Pre IPO Ascent ENT Group Holdings - Conservative About the Outlook

Ascent is the leading private ENT service provider in Singapore, but has to face fierce competition, limited doctor resources and growth ceilings....

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)